Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Truist Financial analyst Joon Lee reiterated a Buy rating on Taysha Gene Therapies (TSHA – Research Report) today. The company’s shares closed ...
Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...